MedTrace Logo

Touchscreen-based Cognitive Tests in Healthy Volunteers

NCT03469089 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2018-10-16

No results posted yet for this study

Summary

This phase Ib study aims to evaluate applicability of touchscreen-based cognitive test battery for assessment of ketamine-induced schizophrenia-like cognitive deficits in healthy volunteers. Additionally, the study aims to assess whether ketamine-induced cognitive deficits are reversed by modafinil using touchscreen-based test battery for testing of cognition.

Conditions

Interventions

DRUG

Ketamine 0.58

Ketamine (0.23 mg/kg bolus + 0.58 mg/kg/h)

DRUG

Ketamine 0.31

Ketamine (0.12 mg/kg bolus + 0.31 mg/kg/h)

DRUG

Modafinil

Modafinil tablet 100 mg placed in a capsule

DRUG

Placebo for ketamine

0.9 % NaCl infusion solution

DRUG

Placebo for modafinil

Placebo capsule for modafinil capsule

Sponsors & Collaborators

  • University of Eastern Finland

    lead OTHER

Principal Investigators

  • Markus M Forsberg, PhD · University of Eastern Finland

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-12
Primary Completion
2018-05-16
Completion
2019-12-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03469089 on ClinicalTrials.gov